



Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY DOCKET NO.  
0459-0554PAPPLICATION NO.  
09/781,893APPLICANT  
Kent JORGENSEN, et al.FILING DATE  
February 9, 2001GROUP  
Unassigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
h	5 8 2 7 8 3 6	1998-10-27	Peterson, et al.			
	5 4 8 4 9 1 1	1996-01-16	Hong, et al.			
	4 6 2 2 3 9 2	1986-11-11	Hong, et al.			
	5 9 4 2 2 4 6	1999-08-24	Mayhew, et al.			
	5 9 3 2 2 4 2	1999-08-03	Franklin, et al.			
	5 9 6 5 1 5 9	1999-10-12	Mayhew, et al.			
	6 0 0 7 8 3 9	1999-12-28	Mayhew, et al.			
	5 8 8 2 6 7 9	1999-03-16	Needham			
	5 9 8 5 8 5 4	1999-11-16	Kozak			
	6 0 7 7 8 3 7	2000-06-20	Kozak			
	6 1 3 6 7 9 6	2000-10-24	Kozak			
	6 1 6 6 0 8 9	2000-12-26	Kozak			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
h	ES 2 0 3 4 8 84	1994-03-01	SPAIN				
	WO 94 0 9 0 1 4	1994-04-28	PCT				
	WO 94 2 2 4 8 3	1994-10-13	PCT				
	WO 99 0 2 1 2 0	1999-01-21	PCT				
	WO 99 0 2 4 8 5	1999-01-21	PCT				
	WO 99 1 6 7 4 1	1999-04-08	PCT				

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

h	"Therapeutic Activity of a Thioether-Lipid Conjugate of 1- $\beta$ -D-Arabinofuranosylcytosine in Human Colorectal Cancer Xenografts", R. Herrmann, et al, Am. Assoc. Cancer Res., Vol. 52, No. 7, pp. 1865-1867 (1992)
	"Competitive Inhibition of Lipolytic Enzymes. IX. A comparative Study on the Inhibition of Pancreatic Phospholipases A <sub>2</sub> from Different Sources by (R)-2-acylamino Phospholipid Analogues", G. H. de Haas, et al, BBA - Lipids and Lipid Metabolism, NL, Elsevier Science BV., Vol. 1167, No. 3, 1993, pp. 281-288
h	"The Chemical Synthesis of a Series of Ether Phospholipids From D-Mannitol and Their Properties", J. Xia, et al, Tetrahedron: Asymmetry, Vol. 8, No. 18, pp. 3131-3142, 1997

EXAMINER

DATE CONSIDERED

8/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

0459-0554P

JAC/cb

Form PTO-1449

# INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

 ATTY DOCKET NO.  
0459-0554P

 APPLICATION NO.  
09/781,893

 APPLICANT  
Kent JORGENSEN, et al.

 FILING DATE  
February 9, 2001

 GROUP  
Unassigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
					YES NO

## OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

m		"Cytotoxicity of Platelet Activating Factor and Related Alkyl-Phospholipid Analogs in Human Leukemia Cells, Polymorphonuclear Neutrophils, and Skin Fibroblasts", D. Hoffman, et al, Blood, Vol. 63, No. 3, 1984, pp. 545-552
		Enzymatic Degradation of Polymer Covered SOPC-Liposomes in Relation to Drug Delivery", J. Davidsen, et al, Symposium on Lipid and Surfactant Self-Assemblies: Structure, Dynamics and Reactions, Feb. 24-25, 2000, Uppsala, Sweden
		"Controlled Destabilization of Liposomal Drug Delivery Systems by Phospholipase A <sub>2</sub> ", J Davidsen, et al, Dec. 1999
		"Increased Cell-surface Receptor Expression on U-937 Cells Induced by 1-0-octadecyl-2-0-methyl-sn-glycero-3-phosphocholine", M. Pushkareva, et al, Cancer Immunol Immunother (2000) 48: 569-578
		"Ether Lipids in the Therapy of Cancer", R. Andreessen, Prog. Biochem, Pharmacol, Vol 22, pp. 118-131 1988
		"1-β-D-Arabinofuranosylcytosine-Phospholipid Conjugates As Prodrugs of Ara-C", C. Hong, et al, Cancer Drug Delivery, Vol. 1, No. 3, 1984, pp. 181-190
		"Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids", C. Hong, et al, J. Med. Chem. 1986, 29, 2038-2044
		"Phospholipid Antitumor Agents", W. Houlihan, et al., Medicinal Research Reviews, Vol. 15, No. 3, 157-223 (1995)
		"Antitumor Ether Lipids and Alkylphosphocholines", M. Lohmeyer, et al, Drugs of the Future, 1994, 19(11): 1021-1037
		"Growth Arrest vs. Direct Cytotoxicity and the Importance of Molecular Structure for the In vitro Anti-Tumor Activity of Ether Lipids", M. Lohmeyer, et al, British Journal of Cancer (1995) 72, pp. 277-286
v		"Enhancement of Phospholipase A <sub>2</sub> Catalyzed Degradation of Polymer Grafted PEG-Liposomes: Effects of Lipopolymer-concentration and Chain-Length", K Jorgensen, et al., Pharmaceutical Research, Vol. 16, No. 9, 1999 pp. 1491-1493
		"Increase in Phospholipase A <sub>2</sub> Activity Towards Lipopolymer-Containing Liposomes, C. Vermehren, et al, BBA, 1998, pp.27-36

EXAMINER

Kjlu

DATE CONSIDERED

8/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.